What "Rx only" on a drug label means

Every prescription drug label in the United States has to carry, at a minimum, the symbol "Rx only." The rule cuts both ways. Under section 503(b)(4) of the Federal Food, Drug, and Cosmetic Act¹, a prescription drug whose label lacks the symbol is misbranded, and so is a nonprescription drug whose label bears it.

That two-word version is fairly new. Until 1997 the law required a longer line: "Caution: Federal law prohibits dispensing without prescription." Congress replaced it with "Rx only" in the Food and Drug Administration Modernization Act of 1997, according to the statutory notes to 21 U.S.C. 353¹, and the change took effect 90 days after the law's Nov. 21, 1997, enactment.

From the pharmacy counter, the prescription line can look permanent. It moves more than most people assume. FDA's own list records 47 approvals since December 2001 that shifted a product, or some of its uses, to nonprescription status, and in openFDA's label data the same molecule frequently appears on both sides of the line at once.

Where the prescription line came from

Within two months of the 1938 Food, Drug, and Cosmetic Act's passage, FDA began identifying drugs, such as the sulfas, that "simply could not be labeled for safe use directly by the patient," according to the agency's history of the act³. That year, FDA's historical timeline² says, the agency stated that sulfanilamide and other dangerous drugs had to be given under the direction of a medical expert, which "begins the requirement for prescription only (nonnarcotic) drugs." For the next 13 years, FDA, industry and health practitioners argued over which drugs belonged in which category. FDA's own history says that debate was "resolved in the Durham-Humphrey Amendment of 1951."³

The Durham-Humphrey Amendment became law on Oct. 26, 1951, and took effect six months later. The legislative note in the U.S. Code describes its two aims: to "protect the public from abuses in the sale of potent prescription drugs, and to relieve retail pharmacists and the public from unnecessary restrictions on the dispensation of drugs that are safe to use without supervision of a doctor," as the annotated statute¹ puts it. In FDA's summary², the amendment "defines the kinds of drugs that cannot be used safely without medical supervision" and limits their sale to prescription, with all other drugs available without one.

The test written into the statute still stands, in slightly edited form. Under 503(b)(1)¹, a drug requires a prescription if, "because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use," it is not safe to use except under a licensed practitioner's supervision, or if its approved application limits it to such use. The same paragraph lets a pharmacist dispense on a written prescription, an oral one "reduced promptly to writing," or an authorized refill. The 1997 law also struck a clause that had listed certain habit-forming drugs as a separate prescription category.

That language is what sits behind the symbol on a manufacturer's stock bottle. The pharmacy label on the vial you take home follows separate requirements, which our guide to reading a prescription label covers.

How a drug moves to the other side

Federal regulations describe the reverse trip. Under 21 CFR 310.200(b)⁴, a drug limited to prescription use under an approved application is exempted when FDA finds the requirement "not necessary for the protection of the public health" and finds the drug "safe and effective for use in self-medication as directed in proposed labeling."

FDA calls this a prescription-to-nonprescription switch⁵ and recognizes two kinds. In a full switch, the drug becomes available only without a prescription. In a partial switch, some uses move to nonprescription status while others stay behind the counter. A company seeking either has to show the drug works and is safe in self-care, and it also has to show that consumers can understand how to use it without a clinician. FDA's 2013 guidance on self-selection studies⁷ describes one kind of evidence for that: trials testing whether people can read a proposed label and correctly decide whether the product is right for them.

A switch is only one way in. A large proportion of nonprescription products reach the market through the OTC monograph pathway instead, according to FDA's switch-list page⁶. FDA's timeline dates the start of the Over-the-Counter Drug Review to 1972², the process that set ingredient-by-ingredient rules, or monographs, for whole categories of products. Those products reach shelves without an individual approval. The switch list only covers products that started out on the prescription side.

Switches by molecule

FDA's Prescription to Nonprescription Switch List⁶, last updated June 16, 2026, has 47 entries. The earliest is dated Dec. 7, 2001. Many entries are separate approvals for the same molecule in different forms. The table below picks one entry per molecule, using the molecule and the nonprescription use as FDA lists them.

The most recent entry on the list, approved on June 16, 2026, is a second naloxone nasal spray, which FDA's list⁶ shows at 4 mg per 0.25 mL.

One molecule, two statuses

A partial switch leaves a molecule with two sets of labels. GxRadar counted label documents in the openFDA drug label dataset⁹, updated Oct. 30, 2026, by whether FDA's harmonized data list each one as a prescription or an over-the-counter product. The counts include combination products whose names contain the molecule, and each document is one product version from one company or repackager.

Label text shows where the line falls. A current over-the-counter omeprazole label in the dataset lists 20 mg per tablet, gives the purpose as "Acid reducer," and lists one use: it "treats frequent heartburn (occurs 2 or more days a week)." A current prescription omeprazole label lists indications that include active duodenal ulcer, eradication of the bacterium H. pylori to reduce the risk of ulcer recurrence, and gastroesophageal reflux disease. Famotidine follows the same pattern (our piece on acid reducer prices tracks the prescription versions), with a 20 mg OTC tablet labeled for heartburn and a prescription label for 40 mg tablets whose indications include active ulcers and erosive esophagitis.

Across the whole dataset, openFDA classifies 47,102 label documents as human OTC drugs and 34,924 as human prescription drugs. The over-the-counter side has its own standardized panel, which our guide to the Drug Facts label walks through, and store-brand versions of switched molecules are covered in our piece on store-brand OTC medicines. How a prescription version and an OTC version compare in cost under a given plan is a question for the plan or the pharmacist, and our explainer on cash prices and copays describes how those quotes differ.

A middle category, still empty

On Dec. 23, 2024, FDA issued a final rule creating a third route: a nonprescription drug with an additional condition for nonprescription use⁸, or ACNU. The rule took effect May 27, 2025. Under it, a consumer would have to complete an extra step, such as a questionnaire, before buying or using the product, for cases where FDA judges the label alone cannot carry everything a person needs to choose and use the drug safely. FDA has said the rule could open nonprescription access to some drugs for chronic conditions.

When GxRadar checked FDA's ACNU page in November 2026, it still said, "Right now, there are no FDA-approved nonprescription drugs with an ACNU." The first approval under the rule would be the first product to sit formally between "Rx only" and the open shelf.